AstraZeneca PLC (NASDAQ:AZN)
| 58.86 Delayed Data As of Jan 14 |  +0.76 / +1.31%Today’s Change | 46.48 Today|||52-Week Range 64.21 | +1.05% Year-to-Date |
Latest AZN News | Press Releases
| 2 Risky Growth Stocks That Could Make You Filthy Rich 10:30am / MotleyFool.com - Paid Partner Content | Better Buy for 2022: Merck vs. AstraZeneca Jan 11 / StockNews.com - Paid Partner Content |
| AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron Jan 14 / Zacks.com - Paid Partner Content | AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate Jan 10 / Zacks.com - Paid Partner Content |
| 1 Top Dividend Stock to Buy and Hold in 2022 and Beyond Jan 13 / MotleyFool.com - Paid Partner Content | 3 Big FDA Approvals to Watch For in Q1 2022 Jan 09 / MotleyFool.com - Paid Partner Content |
| Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug Jan 12 / Zacks.com - Paid Partner Content | 2 Growth Stocks That Are Also Generating Billions in Free Cash Jan 08 / MotleyFool.com - Paid Partner Content |
| Which Vaccine Stocks Will Make You a Fortune in 2022? Jan 12 / MotleyFool.com - Paid Partner Content | Top Stock Reports for Meta Platforms, Bank of America & Mastercard Jan 04 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 58.10 |
| Today’s open | 58.19 |
| Day’s range | 58.17 - 58.98 |
| Volume | 434,735 |
| Average volume (3 months) | 5,023,958 |
| Market cap | $182.4B |
Data as of 4:18pm ET, 01/14/2022
Growth & Valuation
| Earnings growth (last year) | +137.38% |
| Earnings growth (this year) | +29.50% |
| Earnings growth (next 5 years) | +19.56% |
| Revenue growth (last year) | +13.16% |
| P/E ratio | 106.1 |
| Price/Sales | 4.76 |
| Price/Book | 9.89 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVONovo Nordisk | -3.22 | -3.23% |
| NVSNovartis | -0.08 | -0.09% |
| MRKMerck | +0.04 | +0.05% |
| BMYBristol-Myers Squibb | +0.32 | +0.50% |
Data as of 4:23pm ET, 01/14/2022
Financials
| Next reporting date | February 10, 2022 |
| EPS forecast (this quarter) | $0.77 |
| Annual revenue (last year) | $27.6B |
| Annual profit (last year) | $3.2B |
| Net profit margin | 11.58% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Cambridgeshire |
Forecasts
